Last reviewed · How we verify
Mepolizumab SC
Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the immune system.
Mepolizumab is a monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), reducing eosinophil production and activation in the immune system. Used for Severe eosinophilic asthma, Eosinophilic granulomatosis with polyangiitis (EGPA), Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype).
At a glance
| Generic name | Mepolizumab SC |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | IL-5 antagonist monoclonal antibody |
| Target | IL-5 (Interleukin-5) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IL-5 is a key cytokine responsible for eosinophil development, recruitment, and survival. By blocking IL-5, mepolizumab reduces circulating and tissue eosinophil levels, thereby decreasing eosinophil-mediated inflammation. This mechanism is particularly effective in eosinophil-driven diseases such as severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA).
Approved indications
- Severe eosinophilic asthma
- Eosinophilic granulomatosis with polyangiitis (EGPA)
- Chronic rhinosinusitis with nasal polyps (eosinophilic phenotype)
Common side effects
- Headache
- Injection site reactions
- Upper respiratory tract infections
- Fatigue
Key clinical trials
- Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab. (PHASE3)
- Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma
- Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents (PHASE2)
- Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) (PHASE3)
- Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level (PHASE3)
- Identifying Predictors Of Response To Mepolizumab In CRSwNP (PHASE4)
- Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma (PHASE4)
- Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)/ Eosinophilic Chronic Rhinosinusitis (ECRS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |